Both randomized controlled clinical trials and real-word studies of third-generation EGFR TKIs significantly prolonged PFS and OS in patients with advanced EGFR-mutated NSCLC compared to first-generation EGFR-TKIs [26,27]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.